Public Policy Resources

Share

Health Equity in Biomarker Testing and Targeted Therapy

May 12, 2021

Despite evidence demonstrating the effectiveness of biomarker testing and targeted therapy, currently not all individuals benefit equitably from these advances. There are notable racial/ethnic, and socioeconomic disparities in access and utilization of these advancements in care. These disparities in access and use of guideline-indicated biomarker testing and targeted therapy can potentially widen existing disparities in cancer survival.

PDF icon Download Fact Sheet on Health Equity in Biomarker Testing and Targeted Therapy

Related Resources

July 18, 2022

Survivor Views: Copay Assistance and Patient Navigation

Prescription drug costs are a significant burden on cancer patients and survivors, sometimes even leading patients to miss or delay taking prescribed medications. The latest Survivor Views survey explores the role copay assistance programs can play in reducing this burden, and also addresses patient navigation and digital therapeutics.

Read More

ACS CAN Comments on Draft FDA Guidance on Clinical Trial Diversity Plans

June 13, 2022

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) on the Diversity Plans To Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials Draft Guidance for Industry. 

Read more

The National Breast & Cervical Cancer Early Detection Program

May 20, 2022

For 30 years, the Centers for Disease Control and Prevention’s National Breast and Cervical Cancer Early Detection Program has decreased disparities in breast and cervical cancer deaths.

Read more